Moderna to Pay US$950 Million to Settle COVID-19 Vaccine Patent Dispute
Source: Investing News Network
2026-03-05 10:52:29 ET
Moderna (NASDAQ:MRNA) has agreed to pay US$950 million to resolve a long-running patent dispute tied to the technology used in its COVID-19 vaccine.
The pharmaceuticals giant announced it has reached a global settlement with Arbutus Biopharma (NASDAQ:ABUS) and Genevant Sciences GmbH over claims that Moderna’s vaccines infringed patents related to lipid nanoparticle (LNP) delivery technology.
For further details see:
Moderna to Pay US$950 Million to Settle COVID-19 Vaccine Patent Dispute
Moderna Inc.
NASDAQ: MRNA
MRNA Trading
5.97% G/L:
$53.75 Last:
6,303,781 Volume:
$53.30 Open:
MRNA Latest News
MRNA Stock Data
$16,877,354,918
348,095,445
0.39%
298
N/A
Biotechnology & Life Sciences
Healthcare
US
Cambridge
